Meet John V. Oyler

John co-founded BeiGene in 2010 with the aim of building a different kind of oncology company: one capable of doing ambitious science while making medicines more affordable and accessible. Now operating as BeOne Medicines, the company has grown into a global biopharma business with more than 11,000 colleagues across 45 countries and regions, one of the industry’s largest oncology teams, and a pipeline spanning clinical, commercial, and preclinical programs.

Under John’s leadership, BeOne has built an internal clinical development model designed to improve efficiency, execution, and access. Its teams have run more than 140 clinical trials across 45 countries and regions, helping bring its medicines to more than 1.6 million patients worldwide. In 2025, John was named EY World Entrepreneur of the Year, reflecting the scale of what he has built: a global oncology company founded on the idea that innovation and access should advance together.

“When I co-founded BeiGene in 2010, I realized that the rising costs of developing cutting-edge oncology medicines, coupled with persistent barriers to access, were creating a vicious cycle of inequality – where the ‘haves’ had access, and the ‘have-nots’ were left behind in terms of both access to care and affordability.”